Drug Profile
CT 15300
Alternative Names: CT15300Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antirheumatics
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China
- 21 Mar 2017 Preclinical trials in Rheumatoid arthritis in China (unspecified route) (HEC Pharm pipeline, March 2017)
- 21 Mar 2017 HEC Pharm announces intention to submit IND for Rheumatoid arthritis (HEC Pharm pipeline, March 2017)